Research and Development and License Agreements (Details) £ in Thousands					1 Months Ended					6 Months Ended	12 Months Ended
	Mar. 09, 2022 USD ($)	Oct. 11, 2020	Apr. 11, 2019 USD ($)	Jun. 06, 2017 GBP (£)	Mar. 31, 2022 USD ($)	Sep. 17, 2021 USD ($)	Jul. 31, 2021 USD ($)	Aug. 25, 2020	Mar. 19, 2018	Jun. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Apr. 21, 2022 USD ($)	Jan. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)
Research and Development and License Agreements (Details) [Line Items]
Description of lipocure agreement									Under the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030.
Nanomerics collaboration agreement, description			On April 11, 2019, the Company entered into an exclusive collaboration and license agreement, as amended (the “Nanomerics Collaboration Agreement”), with Nanomerics Ltd., a company organized and existing under the laws of United Kingdom (“Nanomerics”), for the exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, to engage in a collaborative program utilizing Nanomerics’ knowledge, skills and expertise in the clinical development of products and to attract external funding for such development.
Research service fees							$ 400,000
Research and development											$ 10,762,670	$ 4,839,115
Description of cooperative research and development agreement								The term of the CRADA is for a period of four years from May 6, 2020 (the effective date of the agreement) and can be terminated by both parties at any time by mutual written consent.
MedPharm License Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone and royalty payments | £				£ 1,150
Nanomerics Collaboration Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Aggregate milestone payments			$ 103,000,000
Amended Nanomerics License Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone and royalty payments	$ 5,500,000
Aggregate milestone payments	112,500,000
Additional aggregate milestone payments	$ 999,999
Nonrefundable fee of research and development expenses					$ 1,500,000
Amended Nanomerics License Agreement [Member] | Minimum [Member]
Research and Development and License Agreements (Details) [Line Items]
Profit share arrangement percentage	30.00%
Percentage of royalties	5.00%
Amended Nanomerics License Agreement [Member] | Maximum [Member]
Research and Development and License Agreements (Details) [Line Items]
Profit share arrangement percentage	40.00%
Percentage of royalties	15.00%
Nanomerics License Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Amount paid for milestone payment						$ 200,000							$ 500,000
Royalty payments						$ 41,000,000
Nanomerics License Agreement [Member] | Minimum [Member]
Research and Development and License Agreements (Details) [Line Items]
Royalty payments percentage						5.00%
Nanomerics License Agreement [Member] | Maximum [Member]
Research and Development and License Agreements (Details) [Line Items]
Royalty payments percentage						15.00%
Yissum Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Description of yissum research agreement		Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of the Company’s IPO, the Company paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement were completed by June 30, 2021.On June 30, 2021, the Company entered into an Agreement for Rendering of Research Services with Yissum (the “June 2021 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the October 2020 Yissum Research Agreement.
Research and development in process										$ 337,500
Lipocure Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Research service fees							$ 200,000
Research service fees paid in quarterly payments														$ 270,000	$ 270,000
Research and development											270,000
Lipocure payment											250,000
Research and development expense											$ 990,000	$ 870,000